Holds 3 active US DMFs and one valid CEP for nilotinib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds 4 active US DMFs and one valid CEP for nilotinib, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for nilotinib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for nilotinib, filing since 2021. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for nilotinib, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for nilotinib, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds 2 active US DMFs for nilotinib, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one valid CEP for nilotinib, filing since 2026. Its GMP is recognised in 2 markets.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Open the full list with a free accountThis page filters the worldwide Nilotinib manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free